Exendin-4 based GLP-1 receptor agonism. 53% homology with human GLP-1. Resistant to DPP-4 degradation. Enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying.
Type 2 diabetes management. First-generation GLP-1 RA — largely superseded by semaglutide and tirzepatide for weight loss efficacy.
MTC history. Severe GI disease. Pancreatitis history.
FDA-approved 2005. EXSCEL CVOT demonstrated CV safety but missed superiority threshold. Post-hoc subanalysis showed potential HF concern in LVEF <40%.
- 1.Holman et al., NEJM 2017 (EXSCEL) — MACE HR 0.91 (95% CI 0.83-1.00). Noninferior (p<0.001), missed superiority (p=0.06). Nominal 14% all-cause mortality reduction. n=14,752
- 2.Eur J Heart Fail 2025 (EXSCEL HF Subanalysis) — HF hospitalization HR 0.74 in LVEF >=40% vs HR 1.52 in LVEF <40% (p-interaction=0.012). Potential concern in reduced EF. Post-hoc subanalysis
Missed superiority for primary MACE endpoint (p=0.06). Mortality reduction nominal, not multiplicity-adjusted. HF concern in LVEF <40% (HR 1.52).
Heart failure subanalysis data: potential concern in reduced EF patients warrants attention.